Center for New Medical Technologies, 630090 Novosibirsk, Russia.
Scientific Research Laboratory, Triangel Scientific, San Francisco, CA 94101, USA.
Nutrients. 2024 Jun 26;16(13):2023. doi: 10.3390/nu16132023.
Emerging evidence suggests that personalized dietary supplement regimens can significantly influence lipid metabolism and cardiovascular risk. The efficacy of AI-guided dietary supplement prescriptions, compared with standard physician-guided prescriptions, remains underexplored. In a randomized, parallel-group pilot study, 70 patients aged 40-75 years with LDL-C levels between 70 and 190 mg/dL were enrolled. Participants were randomized to receive either AI-guided dietary supplement prescriptions or standard physician-guided prescriptions for 90 days. The primary endpoint was the percent change in LDL-C levels. Secondary endpoints included changes in total cholesterol, HDL-C, triglycerides, and hsCRP. Supplement adherence and side effects were monitored. Sixty-seven participants completed the study. The AI-guided group experienced a 25.3% reduction in LDL-C levels (95% CI: -28.7% to -21.9%), significantly greater than the 15.2% reduction in the physician-guided group (95% CI: -18.5% to -11.9%; < 0.01). Total cholesterol decreased by 15.4% (95% CI: -19.1% to -11.7%) in the AI-guided group compared with 8.1% (95% CI: -11.5% to -4.7%) in the physician-guided group ( < 0.05). Triglycerides were reduced by 22.1% (95% CI: -27.2% to -17.0%) in the AI-guided group versus 12.3% (95% CI: -16.7% to -7.9%) in the physician-guided group ( < 0.01). HDL-C and hsCRP changes were not significantly different between groups. The AI-guided group received a broader variety of supplements, including plant sterols, omega-3 fatty acids, red yeast rice, coenzyme Q10, niacin, and fiber supplements. Side effects were minimal and comparable between groups. AI-guided dietary supplement prescriptions significantly reduce LDL-C and triglycerides more effectively than standard physician-guided prescriptions, highlighting the potential for AI-driven personalization in managing hypercholesterolemia.
新出现的证据表明，个性化的膳食补充剂方案可以显著影响脂质代谢和心血管风险。与标准的医生指导处方相比，人工智能指导的膳食补充剂处方的疗效仍未得到充分探索。在一项随机、平行组的试点研究中，纳入了 70 名年龄在 40-75 岁之间、LDL-C 水平在 70-190mg/dL 之间的患者。参与者被随机分为接受人工智能指导的膳食补充剂处方或标准医生指导的处方组，疗程为 90 天。主要终点是 LDL-C 水平的变化百分比。次要终点包括总胆固醇、HDL-C、甘油三酯和 hsCRP 的变化。监测补充剂的依从性和副作用。67 名参与者完成了研究。AI 指导组的 LDL-C 水平降低了 25.3%（95%CI：-28.7%至-21.9%），显著大于医生指导组的 15.2%（95%CI：-18.5%至-11.9%；<0.01）。AI 指导组的总胆固醇降低了 15.4%（95%CI：-19.1%至-11.7%），而医生指导组仅降低了 8.1%（95%CI：-11.5%至-4.7%）（<0.05）。AI 指导组的甘油三酯降低了 22.1%（95%CI：-27.2%至-17.0%），而医生指导组仅降低了 12.3%（95%CI：-16.7%至-7.9%）（<0.01）。HDL-C 和 hsCRP 的变化在两组之间没有显著差异。AI 指导组接受了更广泛的补充剂，包括植物固醇、欧米伽 3 脂肪酸、红曲米、辅酶 Q10、烟酸和纤维补充剂。副作用在两组之间轻微且相似。与标准的医生指导处方相比，人工智能指导的膳食补充剂处方能更有效地降低 LDL-C 和甘油三酯，突出了人工智能驱动的个性化在管理高胆固醇血症方面的潜力。
Zotero 插件